# G2GBIO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/g2gbio

- Industry: Pharmaceuticals
- Headquarters: Cheongju-si, South Korea
- Website: www.g2gbio.com
- Total disclosed funding: $16M
- Latest round: Series B (Jul 21, 2020)
- Investors on record: 10

## About

Based in Cheongju, South Korea, and founded in 2017, G2GBIO, Inc. specializes in the development and manufacturing of innovative injectable drug formulations, focusing on sustained-release microsphere injectables to enhance cancer treatment efficacy. G2GBIO, Inc. develops advanced injectable drug formulations. In March 2026, Samsung Epis Holdings agreed to acquire convertible bonds in G2GBIO, Inc. at KRW 116,900 apiece for KRW 20 billion, in a PIPE transaction. The deal is expected to be completed at the end of the month. The CEO is Hee-yong Lee. G2GBIO, Inc. specializes in the development and manufacturing of injectable drug formulations, particularly focusing on sustained-release microsphere injectables. Their key products include the InteLAMP technology, which enables prolonged release of therapeutics from microspheres and promotes uniform distribution within tumor tissues, effectively targeting and eliminating cancer cells. Their offerings cater to a global client base, including pharmaceutical companies and healthcare providers in markets such as South Korea, Japan, and the broader Asian region, addressing various medical conditions through advanced drug delivery systems. G2GBIO, Inc. generates revenue through strategic partnerships with global pharmaceutical companies for the production and supply of proprietary injectable formulations. The company has raised KRW 5 billion in funding, reflecting strong investor interest in their technologies. Revenue transactions involve contracts for manufacturing sustained-release injectable drugs, with pricing based on customized solutions for client specifications and market needs. The company will use the March 2026 funds for its operations.

## Funding rounds

- Series B, Jul 21, 2020, $9.5M — Seoul Investment Partners, Korea Investment Partners, BNK Venture Capital, IBK Capital, QUAD Ventures, ARK Impact Asset Management, Emford Equity Partners
- Series A, Apr 11, 2018, $6.5M — CKD Venture Capital, Korea Investment Partners, AG Investment, QUAD Ventures, Daedeok Venture Partners

## Investors

- CKD Venture Capital (https://capitalatlas.ai/funds/ckd-venture-capital) — Series A
- Korea Investment Partners (https://capitalatlas.ai/funds/korea-investment-partners) — Series A, Series B
- AG Investment (https://capitalatlas.ai/funds/ag-investment) — Series A
- QUAD Ventures (https://capitalatlas.ai/funds/quad-ventures) — Series A, Series B
- Daedeok Venture Partners (https://capitalatlas.ai/funds/daedeok-venture-partners) — Series A
- Seoul Investment Partners (https://capitalatlas.ai/funds/seoul-investment-partners) — Series B
- BNK Venture Capital (https://capitalatlas.ai/funds/bnk-venture-capital) — Series B
- IBK Capital (https://capitalatlas.ai/funds/ibk-capital) — Series B
- ARK Impact Asset Management — Series B
- Emford Equity Partners (https://capitalatlas.ai/funds/emford-equity-partners) — Series B